By Fineline Cube 
Brii Biosciences Limited (HKG: 2137) announced a collaboration with OpenBench to leverage its structure‑driven Artificial Intelligence (AI) platform, accelerating innovative drug discovery and applying proprietary screening technology to specified targets.
Transaction Overview
| Component | Details |
|---|---|
| Partnership Scope | Multi‑target drug discovery collaboration |
| OpenBench Role | Deliver novel lead compounds meeting Brii’s requirements using AI platform |
| Brii Biosciences Rights | Exclusive rights to discovered lead compounds; exclusive access to OpenBench’s screening technology for specified targets |
| OpenBench Compensation | Corresponding compensation per delivered compound (terms undisclosed) |
| Scalability | Collaboration may extend to additional R&D projects as needed |
| Technology Focus | Structure‑driven AI platform for lead compound identification |
Strategic Implications
| Party | Benefit |
|---|---|
| Brii Biosciences | Accelerates R&D timeline; gains access to cutting‑edge AI screening; expands innovative pipeline with exclusive assets |
| OpenBench | Monetizes AI platform; validates technology via partnership with publicly‑traded biotech; potential for expanded scope and revenue |
| Market Context | AI‑driven drug discovery market projected at $5.8 billion by 2032; partnerships with HKEX‑listed companies enhance credibility and funding pathways |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s expansion potential, R&D acceleration, and technology validation. Actual results may differ due to scientific risks, competitive dynamics, or integration challenges.-Fineline Info & Tech